Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clml.2015.11.007 | DOI Listing |
Life (Basel)
September 2024
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania.
Autoimmune blistering diseases represent a group of chronic severe, disabling, and potentially fatal disorders of the skin and/or mucous membranes, primarily mediated by pathogenic auto-antibodies. Despite their rarity, these diseases are associated with significant morbidity and mortality and profound negative impact on the patient's quality of life and impose a considerable economic burden. Rituximab, an anti-CD-20 monoclonal antibody, represents the first line of therapy for pemphigus, regardless of severity and a valuable off-label therapeutic alternative for subepidermal autoimmune blistering diseases as it ensures high rates of rapid, long-lasting complete remission.
View Article and Find Full Text PDFAdv Exp Med Biol
October 2024
Department of Radiation Oncology, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany.
Clin Cosmet Investig Dermatol
August 2024
Universidad Simón Bolívar. Facultad de Ciencias de la Salud, Centro de Investigaciones de Ciencias de la Vida (CICV), Barranquilla, Colombia.
Transl Pediatr
June 2024
Department of General Surgery, Tianjin Children's Hospital (Children's Hospital, Tianjin University), Tianjin, China.
Background: Acral persistent papular mucinosis (APPM) is a rare idiopathic subtype of localized lichen myxedematosus. To date, there have been less than 41 APPM cases reported worldwide, however, almost all patients were older than 18 years of age. A 7-year-old child was first reported in this paper.
View Article and Find Full Text PDFJ Dermatol
December 2024
Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!